Glaxosmi. Pharma
Glaxosmithkline Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
GSK India targets sustained double-digit growth in coming quarters, aiming for 13-14% CAGR to achieve INR 8,000 crores revenue in 4-5 years. GSK India aims for sustained double-digit top-line growth, targeting around 13%-14% CAGR to reach INR 8,000 crores in 4-5 years. - Growth drivers include both the large established general medicines business (expected to grow 8%-10%) and innovative specialty products (high-growth segments like oncology and respiratory). - Innovation portfolio contribution has doubled recently to 7% of total revenues, materially impacting growth. - EBITDA growth ran slightly ahead of sales with a 17% increase vs.
From Glaxosmi. Pharma's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- GSK India targets sustained double-digit growth in coming quarters, aiming for 13-14% CAGR to achieve INR 8,000 crores revenue in 4-5 years.
- Growth drivers include innovation portfolio growing from 4% to 7% of sales, with oncology, new respiratory, and adult vaccines leading.
- General medicines remain relevant, expected to grow 8-10%.
- Oncology is a fastest-growing segment (industry growth 27% vs. 12-13% overall), providing significant uplift.
- Innovation assets like Shingrix (+65% growth), Nucala (doubling new patients treated), and Trelegy Ellipta continue strong momentum.
- New launches such as Jemperli, Zejula, Blenrep, Ojjaara, and Arexvy expected to contribute to growth.
2 more points from Glaxosmi. Pharma's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Glaxosmi. Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- There is significant investment in front-loading activities such as medical oncologist speaker programs and evidence generation, which likely involve capital allocation towards marketing and scientific dissemination.
- The company is focused on building and scaling innovative portfolios like oncology, respiratory, and vaccines, implying ongoing strategic investments.
- Manufacturing capacity includes a setup in Nashik for local production of general medicines, with 20 contract manufacturers supplementing production, indicating capital investment in local manufacturing infrastructure.
2 more points from Glaxosmi. Pharma's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Glaxosmi. Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Glaxosmi. Pharma said on order book & pipeline — free account, 30 seconds.
Glaxosmi. Pharma — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹995 Cr, net profit ₹278 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Glaxosmi. Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Glaxosmi. Pharma and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Glaxosmi. Pharma Q1 FY27 results?
GSK India targets sustained double-digit growth in coming quarters, aiming for 13-14% CAGR to achieve INR 8,000 crores revenue in 4-5 years. GSK India aims for sustained double-digit top-line growth, targeting around 13%-14% CAGR to reach INR 8,000 crores in 4-5 years. - Growth drivers include both the large established general medicines business (expected to grow 8%-10%) and innovative specialty products (high-growth segments like oncology and respiratory). - Innovation portfolio contribution has doubled recently to 7% of total revenues, materially impacting growth. - EBITDA growth ran slightly ahead of sales with a 17% increase vs.
What is Glaxosmi. Pharma share price analysis?
Glaxosmi. Pharma currently shows a below-average growth signal. The stock trades at a P/E of 41.3 with a market cap of ₹43,471 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Glaxosmi. Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.